Clinical trial
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
NCT00005633 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005633 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma |
| Official title | Vaccination of Melanoma Patients With Tyrosinase YMD and gp100 IMD-Javelin Fusion Peptides/HSP70 Complexes: A Trial Comparing the Immunogenicity of Three Doses |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | OVA BiP peptide, gp209-2M antigen, recombinant 70-kD heat-shock protein, tyrosinase peptide |
| Start date | Jun 1, 1999 |
| Primary completion | Jun 1, 2002 |
| Completion | Jun 1, 2002 |
| First posted | Jul 26, 2004 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: